Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

126 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment Registry.
van Breeschoten J, van den Eertwegh AJM, Hilarius DL, Haanen JB, Blank CU, Aarts MJB, van den Berkmortel FWPJ, de Groot JWB, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Stevense-den Boer MA, van der Veldt AAM, Vreugdenhil G, Boers-Sonderen MJ, Manevski D, Suijkerbuijk KPM, Wouters MWJM, de Wreede LC. van Breeschoten J, et al. Eur J Cancer. 2023 Mar;182:132-143. doi: 10.1016/j.ejca.2023.01.006. Epub 2023 Jan 17. Eur J Cancer. 2023. PMID: 36773402 Free article.
CT radiomics compared to a clinical model for predicting checkpoint inhibitor treatment outcomes in patients with advanced melanoma.
Ter Maat LS, van Duin IAJ, Elias SG, Leiner T, Verhoeff JJC, Arntz ERAN, Troenokarso MF, Blokx WAM, Isgum I, de Wit GA, van den Berkmortel FWPJ, Boers-Sonderen MJ, Boomsma MF, van den Eertwegh FJM, de Groot JWB, Piersma D, Vreugdenhil A, Westgeest HM, Kapiteijn E, van Diest PJ, Pluim JPW, de Jong PA, Suijkerbuijk KPM, Veta M. Ter Maat LS, et al. Eur J Cancer. 2023 May;185:167-177. doi: 10.1016/j.ejca.2023.02.017. Epub 2023 Feb 24. Eur J Cancer. 2023. PMID: 36996627 Free article.
[No title available]
[No authors listed] [No authors listed] PMID: 36319872
Genetic Aspects and Molecular Testing in Prostate Cancer: A Report from a Dutch Multidisciplinary Consensus Meeting.
Mehra N, Kloots I, Vlaming M, Aluwini S, Dewulf E, Oprea-Lager DE, van der Poel H, Stoevelaar H, Yakar D, Bangma CH, Bekers E, van den Bergh R, Bergman AM, van den Berkmortel F, Boudewijns S, Dinjens WNM, Fütterer J, van der Hulle T, Jenster G, Kroeze LI, van Kruchten M, van Leenders G, van Leeuwen PJ, de Leng WWJ, van Moorselaar RJA, Noordzij W, Oldenburg RA, van Oort IM, Oving I, Schalken JA, Schoots IG, Schuuring E, Smeenk RJ, Vanneste BGL, Vegt E, Vis AN, de Vries K, Willemse PM, Wondergem M, Ausems M. Mehra N, et al. Eur Urol Open Sci. 2023 Jan 25;49:23-31. doi: 10.1016/j.euros.2022.11.011. eCollection 2023 Mar. Eur Urol Open Sci. 2023. PMID: 36874601 Free PMC article.
Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocol.
Janssen JC, van Dijk B, de Joode K, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Boers-Sonderen MJ, van den Eertwegh AJM, de Groot JWB, Jalving M, de Jonge MJA, Joosse A, Kapiteijn E, Kamphuis-Huismans AM, Naipal KAT, Piersma D, Rikhof B, Westgeest HM, Vreugdenhil G, Oomen-de Hoop E, Mulder EEAP, van der Veldt AAM. Janssen JC, et al. BMC Cancer. 2024 May 23;24(1):632. doi: 10.1186/s12885-024-12336-0. BMC Cancer. 2024. PMID: 38783238 Free PMC article.
Seasonal variation of anti-PD-1 outcome in melanoma-Results from a Dutch patient cohort.
Borgers JSW, Burgers FH, Schina A, Van Not OJ, van den Eertwegh AJM, Blank CU, Aarts MJB, van den Berkmortel FWPJ, de Groot JWB, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Boer AMS, van der Veldt AAM, Vreugdenhil G, Boers-Sonderen MJ, Wouters MWJM, Suijkerbuijk KPM, van Thienen JV, Haanen JBAG. Borgers JSW, et al. Pigment Cell Melanoma Res. 2024 Jan;37(1):15-20. doi: 10.1111/pcmr.13117. Epub 2023 Aug 8. Pigment Cell Melanoma Res. 2024. PMID: 37554041
Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma.
Leek LVM, Notohardjo JCL, de Joode K, Velker EL, Haanen JBAG, Suijkerbuijk KPM, Aarts MJB, de Groot JWB, Kapiteijn E, van den Berkmortel FWPJ, Westgeest HM, de Gruijl TD, Retel VP, Cuppen E, van der Veldt AAM, Labots M, Voest EE, van de Haar J, van den Eertwegh AJM. Leek LVM, et al. Sci Rep. 2024 May 16;14(1):11244. doi: 10.1038/s41598-024-61150-y. Sci Rep. 2024. PMID: 38755213 Free PMC article.
Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma.
van Not OJ, Verheijden RJ, van den Eertwegh AJM, Haanen JBAG, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Boers-Sonderen MJ, de Groot JB, Hospers GAP, Kamphuis AM, Kapiteijn E, May AM, de Meza MM, Piersma D, van Rijn R, Stevense-den Boer MA, van der Veldt AAM, Vreugdenhil G, Blokx WAM, Wouters MJM, Suijkerbuijk KPM. van Not OJ, et al. JAMA Oncol. 2022 Dec 1;8(12):1794-1801. doi: 10.1001/jamaoncol.2022.5041. JAMA Oncol. 2022. PMID: 36301521 Free PMC article.
Adjuvant treatment of in-transit melanoma: Narrowing the knowledge gap left by clinical trials.
de Meza MM, Blokx WAM, Bonenkamp HJ, Blank CU, Aarts MJB, van den Berkmortel FWPJ, Boers-Sonderen MJ, de Groot JWB, Haanen JB, Hospers GAP, Kapiteijn EW, van Not OJ, Piersma D, van Rijn RS, Stevense-Den Boer MA, van der Veldt AAM, Vreugdenhil G, van den Eertwegh AJM, Suijkerbuijk KPM, Wouters MWJM. de Meza MM, et al. Int J Cancer. 2023 Jul 15;153(2):389-398. doi: 10.1002/ijc.34485. Epub 2023 Mar 8. Int J Cancer. 2023. PMID: 36843260
126 results